Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392710 | 0.77 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL6692500 | 0.70 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL4387887 | 0.68 | CRBN (0.77) | CRBNDDB1 | |
| SCHEMBL25170829 | 0.64 | ALDH1A1 (0.78) | ALDH1A1CDC25BCASP6RCE1 | |
| SCHEMBL29861837 | 0.64 | ALDH1A1 (1.00) | ALDH1A1CDC25BCASP6RCE1 | |
| SCHEMBL29832194 | 0.64 | ALDH1A1 (1.00) | ALDH1A1CDC25BCASP6RCE1 | |
| SCHEMBL107442 | 0.64 | ALDH1A1 (1.00) | ALDH1A1CDC25BCASP6RCE1 | |
| SCHEMBL30291197 | 0.64 | ALDH1A1 (0.78) | ALDH1A1CDC25BCASP6RCE1 | |
| SCHEMBL4394602 | 0.63 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL4395682 | 0.63 | CRBN (1.00) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6656937-B2 | Immunology moderators; interleukin antagonist; anticancer agents | GRUENENTHAL, GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885ALDH1A1 142/4885CDC25B 2801/4885 |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885ALDH1A1 142/4885CDC25B 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.